Company: SCYX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0000950170-25-107985
Chunk: 6

Company: SCYNEXIS INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 6
---
 the study. We do not believe that GSK currently has the right to unilaterally terminate the MARIO study under the GSK License Agreement.

Pursuant to the GSK License Agreement, we are responsible for conducting the MARIO study. The GSK License Agreement provides that certain material changes to the study, including termination, require mutual written agreement of both parties. We have not provided such agreement; in fact, GSK did not give any indication of an intent to terminate the MARIO study until the day it sent its notice. The GSK License Agreement only provides GSK with a unilateral termination right in the event that dosage of the first new patient in MARIO had not occurred by a particular date. The date was set as April 26, 2025, subject to automatic extension of up to two months if the implementation of additional in process control method validation